Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis

Author(s): Sean Knight, Mary Collins, Yasuhiro Takeuchi

Journal Name: Current Gene Therapy

Volume 13 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


Retroviral vectors derived from gammaretroviruses or lentiviruses have now been used extensively in clinical gene therapy trials for several diseases including primary immunodeficiencies, beta thalassaemia and adrenoleukodystrophy. Their utility in this setting has been readily demonstrated by the largely favourable outcomes in recent clinical trials, however this success has been marred by the emergence of malignancies in some trials. These malignancies were a consequence of perturbation of cellular proto-oncogene expression by the integrated retroviral vectors, the process of which is referred to as ‘insertional mutagenesis’ (IM). In this review, the origins of our understanding of IM are reviewed and applied to the clinical gene therapy trials conducted with retroviral vectors. Old and new methods for assessing this phenomenon are discussed with a view to provide a comprehensive account of this emerging field.

Keywords: Retroviral vector, lentiviral vector, insertional mutagenesis.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 02 May, 2013
Page: [211 - 227]
Pages: 17
DOI: 10.2174/1566523211313030006

Article Metrics

PDF: 83